Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × Plasmablastic Lymphoma × Clear all

Phase

Phase 1 2 Phase EARLY_PHASE1 1 Phase 2 1

Status

Terminated 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 298 Carcinoma, Non-Small-Cell Lung 287 Prostatic Neoplasms 160 Colorectal Neoplasms 155 Carcinoma, Hepatocellular 142 Neoplasms 139 Leukemia, Myeloid, Acute 128 Lung Neoplasms 117 Multiple Myeloma 106 Squamous Cell Carcinoma of Head and Neck 105 Triple Negative Breast Neoplasms 97 Pancreatic Neoplasms 95 Recurrence 94 Stomach Neoplasms 93 Neoplasm Metastasis 92 Ovarian Neoplasms 86 Lymphoma, Large B-Cell, Diffuse 77 Sarcoma 73 Esophageal Neoplasms 71 Melanoma 70 Uterine Cervical Neoplasms 68 Precursor Cell Lymphoblastic Leukemia-Lymphoma 65 Brain Neoplasms 65 Rectal Neoplasms 61 Glioblastoma 61 Head and Neck Neoplasms 58 Carcinoma, Renal Cell 56 Myelodysplastic Syndromes 54 Leukemia, Lymphocytic, Chronic, B-Cell 53 Endometrial Neoplasms 53

Interventions

daratumumab 1 Dexamethasone 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04915248 2025-12-24

FIL_DALYA

Fondazione Italiana Linfomi - ETS

Phase 2 Recruiting

Plasmablastic Lymphoma, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡